Literature DB >> 21508696

Recurrent endometrial cancer.

Marcela G Del Carmen1, David M Boruta, John O Schorge.   

Abstract

Endometrial cancer is the most common gynecologic malignancy in the United States. The majority of women are diagnosed with early-stage, low-grade endometrioid tumors that are highly curable with primary surgery. Patients with more advanced and/or higher grade disease require multimodality therapy and have a higher risk for recurrence. Although uterine papillary serous carcinoma and clear cell carcinoma are diagnosed infrequently, they account for almost half of all relapses. As women with recurrent endometrial cancer constitute a heterogeneous group, an individualized approach is required. We review the treatment options of surgery, radiation, hormonal therapy, cytotoxic chemotherapy, and biological agents.

Entities:  

Mesh:

Year:  2011        PMID: 21508696     DOI: 10.1097/GRF.0b013e318218c6d1

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  17 in total

1.  Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells.

Authors:  Joshua Kilgore; Amanda L Jackson; Leslie H Clark; Hui Guo; Lu Zhang; Hannah M Jones; Timothy P Gilliam; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Authors:  Elisabeth J Diver; Rosemary Foster; Bo R Rueda; Whitfield B Growdon
Journal:  Oncologist       Date:  2015-06-22

3.  Analysis of recurrence and survival rates in grade 3 endometrioid endometrial carcinoma.

Authors:  Jieyu Wang; Nan Jia; Qing Li; Chao Wang; Xiang Tao; Keqin Hua; Weiwei Feng
Journal:  Oncol Lett       Date:  2016-07-28       Impact factor: 2.967

4.  Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer.

Authors:  Tianbo Liu; Hongyu Gao; Meng Yang; Tingting Zhao; Yunduo Liu; Ge Lou
Journal:  Tumour Biol       Date:  2014-03-04

5.  Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer.

Authors:  Shervin M Shirvani; Ann H Klopp; Anna Likhacheva; Anuja Jhingran; Pamela T Soliman; Karen H Lu; Patricia J Eifel
Journal:  Pract Radiat Oncol       Date:  2012-05-03

6.  TESTIN suppresses tumor growth and invasion via manipulating cell cycle progression in endometrial carcinoma.

Authors:  Zhenpeng Gu; Guofeng Ding; Kuixiang Liang; Hongtao Zhang; Guanghong Guo; Lili Zhang; Jinxiu Cui
Journal:  Med Sci Monit       Date:  2014-06-14

7.  Unusual Presentation of Recurrent Early Stage Endometrial Carcinoma 28 Years after Primary Surgery.

Authors:  Alessandro Franchello; Gianruggero Fronda; Giacomo Deiro; Alessia Fiore; Davide Cassine; Luca Molinaro; Luigi Chiusa; Sara Galati; Andrea Resegotti; Stefano Silvestri
Journal:  Case Rep Surg       Date:  2015-12-09

Review 8.  New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care.

Authors:  A Talhouk; J N McAlpine
Journal:  Gynecol Oncol Res Pract       Date:  2016-12-13

9.  Stratification of risk groups according to survival after recurrence in endometrial cancer patients.

Authors:  Seung-Hyuk Shim; Dae-Yeon Kim; Hyun Jung Kim; Shin-Wha Lee; Jeong-Yeol Park; Dae-Shik Suh; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

10.  Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer.

Authors:  Runmin Wei; Immaculata De Vivo; Sijia Huang; Xun Zhu; Harvey Risch; Jason H Moore; Herbert Yu; Lana X Garmire
Journal:  Oncotarget       Date:  2016-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.